Total Payments
$11,916
2024 Payments
$5,596
Companies
59
Transactions
430
Medicare Patients
1,578
Medicare Billing
$227,631
Payment Breakdown by Category
Food & Beverage$8,871 (74.4%)
Consulting$2,475 (20.8%)
Education$369.92 (3.1%)
Other$200.00 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,871 | 419 | 74.4% |
| Consulting Fee | $2,475 | 3 | 20.8% |
| Education | $369.92 | 7 | 3.1% |
| Honoraria | $200.00 | 1 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $2,178 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,789 | 57 | $0 (2024) |
| PFIZER INC. | $621.58 | 36 | $0 (2024) |
| Daiichi Sankyo Inc. | $614.87 | 24 | $0 (2024) |
| Lilly USA, LLC | $473.85 | 29 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $444.38 | 18 | $0 (2024) |
| Incyte Corporation | $400.49 | 18 | $0 (2024) |
| Astellas Pharma US Inc | $374.71 | 14 | $0 (2024) |
| ABBVIE INC. | $358.44 | 19 | $0 (2024) |
| Exelixis Inc. | $353.10 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,596 | 238 | AstraZeneca Pharmaceuticals LP ($1,138) |
| 2023 | $4,256 | 93 | Janssen Biotech, Inc. ($2,073) |
| 2022 | $547.00 | 25 | Incyte Corporation ($129.48) |
| 2021 | $123.01 | 7 | Seagen Inc. ($44.79) |
| 2020 | $411.20 | 22 | Lilly USA, LLC ($79.88) |
| 2019 | $821.97 | 40 | AstraZeneca Pharmaceuticals LP ($130.58) |
| 2018 | $146.06 | 4 | AstraZeneca Pharmaceuticals LP ($107.90) |
| 2017 | $15.41 | 1 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($15.41) |
All Payment Transactions
430 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $33.55 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Oncology | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.50 | General |
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.21 | General |
| 12/02/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Oncology | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $24.86 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $31.16 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: Genetic Disease | ||||||
| 11/14/2024 | SERVIER PHARMACEUTICALS LLC | Voranigo (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.62 | General |
| 11/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $34.55 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Oncology | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/05/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $27.48 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 1,055 | 27,581 | $505,836 | $143,015 |
| 2022 | 15 | 523 | 3,741 | $315,590 | $84,616 |
Total Patients
1,578
Total Services
31,322
Medicare Billing
$227,631
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 2,460 | $159,960 | $42,267 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 195 | 304 | $43,004 | $20,308 | 47.2% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 17 | 22,500 | $59,625 | $19,710 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 105 | 129 | $25,077 | $13,034 | 52.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 62 | 62 | $21,045 | $10,534 | 50.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 36 | 68 | $44,121 | $7,411 | 16.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 40 | $15,960 | $5,546 | 34.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $11,552 | $4,879 | 42.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 21 | $5,727 | $3,018 | 52.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 33 | 54 | $11,860 | $2,866 | 24.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 19 | 36 | $7,380 | $2,151 | 29.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 142 | 270 | $9,450 | $2,041 | 21.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 39 | 49 | $5,635 | $1,966 | 34.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 35 | 149 | $13,495 | $1,932 | 14.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 24 | $7,320 | $1,304 | 17.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 101 | 159 | $2,713 | $1,250 | 46.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 39 | 87 | $6,758 | $962.68 | 14.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 16 | 33 | $4,631 | $798.93 | 17.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 22 | $3,027 | $520.70 | 17.2% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 17 | 390 | $46,140 | $344.30 | 0.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 25 | 634 | $870.00 | $133.59 | 15.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 16 | 25 | $205.00 | $21.44 | 10.5% |
| J3490 | Unclassified drugs | Office | 2023 | 15 | 26 | $281.00 | $15.88 | 5.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 13 | 2,280 | $132,240 | $37,963 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 106 | $23,744 | $11,383 | 47.9% |
About Eric Fox
Eric Fox is a Hematology & Oncology healthcare provider based in Bryn Mawr, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2016. The National Provider Identifier (NPI) number assigned to this provider is 1417310038.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Eric Fox has received a total of $11,916 in payments from pharmaceutical and medical device companies, with $5,596 received in 2024. These payments were reported across 430 transactions from 59 companies. The most common payment nature is "Food and Beverage" ($8,871).
As a Medicare-enrolled provider, Fox has provided services to 1,578 Medicare beneficiaries, totaling 31,322 services with total Medicare billing of $227,631. Data is available for 2 years (2022–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Bryn Mawr, PA
- Active Since 03/31/2016
- Last Updated 08/09/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1417310038
Products in Payments
- IMBRUVICA (Drug) $2,154
- IMFINZI (Biological) $630.46
- ENHERTU (Biological) $424.17
- CABOMETYX (Drug) $353.10
- KEYTRUDA (Biological) $352.87
- VERZENIO (Drug) $309.06
- OPDIVO (Biological) $303.59
- Enhertu (Drug) $268.18
- CALQUENCE (Drug) $256.61
- Lenvima (Drug) $235.78
- Onivyde (Drug) $190.39
- ELIQUIS (Drug) $183.56
- JAKAFI (Drug) $181.19
- IBRANCE (Drug) $177.57
- MONJUVI (Drug) $156.86
- INLYTA (Drug) $154.62
- INJECTAFER (Drug) $146.69
- KRAZATI (Drug) $143.57
- XPOVIO (Drug) $140.43
- REBLOZYL (Biological) $137.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Bryn Mawr
Dr. Sameer Gupta, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $348,378
Hematology & Oncology $348,378
Dr. John Devlin, M.d, M.D
Hematology & Oncology — Payments: $29,172
Hematology & Oncology $29,172
Dr. Sandra Schnall, M.d, M.D
Hematology & Oncology — Payments: $10,386
Hematology & Oncology $10,386
Dr. John Garofalo, Md, MD
Hematology & Oncology — Payments: $15.05
Hematology & Oncology $15.05